|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Lapidot T, Sirard C, Vormoor J, Murdoch B,
Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA and
Dick JE: A cell initiating human acute myeloid leukaemia after
transplantation into SCID mice. Nature. 367:645–648.
1994.PubMed/NCBI View
Article : Google Scholar
|
|
3
|
Bonnet D and Dick JE: Human acute myeloid
leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat Med. 3:730–737. 1997.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Konopleva MY and Jordan CT: Leukemia stem
cells and microenvironment: Biology and therapeutic targeting. J
Clin Oncol. 29:591–599. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Lane SW, Wang YJ, Lo Celso C, Ragu C,
Bullinger L, Sykes SM, Ferraro F, Shterental S, Lin CP, Gilliland
DG, et al: Differential niche and Wnt requirements during acute
myeloid leukemia progression. Blood. 118:2849–2856. 2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Valent P, Sadovnik I, Eisenwort G, Bauer
K, Herrmann H, Gleixner KV, Schulenburg A, Rabitsch W, Sperr WR and
Wolf D: Immunotherapy based targeting and elimination of leukemic
stem cells in AML and CML. Int J Mol Sci. 20(4233)2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Yates JW, Wallace HJ Jr, Ellison RR and
Holland JF: Cytosine arabinoside (NSC-63878) and daunorubicin
(NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer
Chemother Rep. 57:485–488. 1973.PubMed/NCBI
|
|
8
|
Burnett A, Wetzler M and Löwenberg B:
Therapeutic advances in acute myeloid leukemia. J Clin Oncol.
29:487–494. 2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Bose P, Vachhani P and Cortes JE:
Treatment of relapsed/refractory acute myeloid leukemia. Curr Treat
Options Oncol. 18(17)2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kantarjian H, Oki Y, Garcia-Manero G,
Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F,
Estrov Z, et al: Results of a randomized study of 3 schedules of
low-dose decitabine in higher-risk myelodysplastic syndrome and
chronic myelomonocytic leukemia. Blood. 109:52–57. 2007.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Oki Y, Aoki E and Issa JP:
Decitabine--bedside to bench. Crit Rev Oncol Hematol. 61:140–152.
2007.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Oki Y and Issa JP: Treatment options in
advanced myelodysplastic syndrome, with emphasis on epigenetic
therapy. Int J Hematol. 86:306–314. 2007.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ding L, Qiu L, Zhang J and Guo B:
Camptothecin-induced cell proliferation inhibition and apoptosis
enhanced by DNA methyltransferase inhibitor,
5-aza-2'-deoxycytidine. Biol Pharm Bull. 32:1105–1108.
2009.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Turcan S, Fabius AW, Borodovsky A, Pedraza
A, Brennan C, Huse J, Viale A, Riggins GJ and Chan TA: Efficient
induction of differentiation and growth inhibition in IDH1 mutant
glioma cells by the DNMT Inhibitor Decitabine. Oncotarget.
4:1729–1736. 2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Fribley A, Zeng Q and Wang CY: Proteasome
inhibitor PS-341 induces apoptosis through induction of endoplasmic
reticulum stress-reactive oxygen species in head and neck squamous
cell carcinoma cells. Mol Cell Biol. 24:9695–9704. 2004.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Fribley A and Wang CY: Proteasome
inhibitor induces apoptosis through induction of endoplasmic
reticulum stress. Cancer Biol Ther. 5:745–748. 2006.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Cortes J, Thomas D, Koller C, Giles F,
Estey E, Faderl S, Garcia-Manero G, McConkey D, Ruiz SL,
Guerciolini R, et al: Phase I study of bortezomib in refractory or
relapsed acute leukemias. Clin Cancer Res. 10:3371–3376.
2004.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Attar EC, De Angelo DJ, Supko JG, D'Amato
F, Zahrieh D, Sirulnik A, Wadleigh M, Ballen KK, McAfee S, Miller
KB, et al: Phase I and pharmacokinetic study of bortezomib in
combination with idarubicin and cytarabine in patients with acute
myelogenous leukemia. Clin Cancer Res. 14:1446–1454.
2008.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann
E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, et al:
Bortezomib induces DNA hypomethylation and silenced gene
transcription by interfering with Sp1/NF-kappaB-dependent DNA
methyltransferase activity in acute myeloid leukemia. Blood.
111:2364–2373. 2008.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Liu S, Wu LC, Pang J, Santhanam R, Schwind
S, Wu YZ, Hickey CJ, Yu J, Becker H, Maharry K, et al:
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid
leukemia. Cancer Cell. 17:333–347. 2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Klco JM, Spencer DH, Lamprecht TL,
Sarkaria SM, Wylie T, Magrini V, Hundal J, Walker J, Varghese N,
Erdmann-Gilmore P, et al: Genomic impact of transient low-dose
decitabine treatment on primary AML cells. Blood. 121:1633–1643.
2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Roccaro AM, Hideshima T, Raje N, Kumar S,
Ishitsuka K, Yasui H, Shiraishi N, Ribatti D, Nico B, Vacca A, et
al: Bortezomib mediates antiangiogenesis in multiple myeloma via
direct and indirect effects on endothelial cells. Cancer Res.
66:184–191. 2006.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Tomikoshi Y, Nomura M, Okudaira N,
Sakagami H and Wakabayashi H: Enhancement of cytotoxicity of three
apoptosis-inducing agents against human oral squamous cell
carcinoma cell line by benzoxazinotropone. In Vivo. 30:645–650.
2016.PubMed/NCBI
|
|
25
|
Iijima Y, Bandow K, Sano M, Hino S, Kaneko
T, Horie N and Sakagami H: In vitro assessment of antitumor
potential and combination effect of classical and
molecular-targeted anticancer drugs. Anticancer Res. 39:6673–6684.
2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Jabbour E, Issa JP, Garcia-Manero G and
Kantarjian H: Evolution of decitabine development: Accomplishments,
ongoing investigations, and future strategies. Cancer.
112:2341–2351. 2008.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Erba HP: Finding the optimal combination
therapy for the treatment of newly diagnosed AML in older patients
unfit for intensive therapy. Leuk Res. 39:183–191. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Welch JS, Petti AA, Miller CA, Fronick CC,
O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon
B, et al: TP53 and Decitabine in Acute Myeloid Leukemia and
Myelodysplastic Syndromes. N Engl J Med. 375:2023–2036.
2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Tamamyan G, Kadia T, Ravandi F, Borthakur
G, Cortes J, Jabbour E, Daver N, Ohanian M, Kantarjian H and
Konopleva M: Frontline treatment of acute myeloid leukemia in
adults. Crit Rev Oncol Hematol. 110:20–34. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Blum W, Garzon R, Klisovic RB, Schwind S,
Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, et al:
Clinical response and miR-29b predictive significance in older AML
patients treated with a 10-day schedule of decitabine. Proc Natl
Acad Sci USA. 107:7473–7478. 2010.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Ritchie EK, Feldman EJ, Christos PJ, Rohan
SD, Lagassa CB, Ippoliti C, Scandura JM, Carlson K and Roboz GJ:
Decitabine in patients with newly diagnosed and relapsed acute
myeloid leukemia. Leuk Lymphoma. 54:2003–2007. 2013.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Bhatnagar B, Duong VH, Gourdin TS, Tidwell
ML, Chen C, Ning Y, Emadi A, Sausville EA and Baer MR: Ten-day
decitabine as initial therapy for newly diagnosed patients with
acute myeloid leukemia unfit for intensive chemotherapy. Leuk
Lymphoma. 55:1533–1537. 2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Khan N, Hantel A, Knoebel RW, Artz A,
Larson RA, Godley LA, Thirman MJ, Liu H, Churpek JE, King D, et al:
Efficacy of single-agent decitabine in relapsed and refractory
acute myeloid leukemia. Leuk Lymphoma. 58:1–7. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Stresemann C, Bokelmann I, Mahlknecht U
and Lyko F: Azacytidine causes complex DNA methylation responses in
myeloid leukemia. Mol Cancer Ther. 7:2998–3005. 2008.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Valdez BC, Li Y, Murray D, Corn P,
Champlin RE and Andersson BS: 5-Aza-2'-deoxycytidine sensitizes
busulfan-resistant myeloid leukemia cells by regulating expression
of genes involved in cell cycle checkpoint and apoptosis. Leuk Res.
34:364–372. 2010.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Tsujioka T, Yokoi A, Uesugi M, Kishimoto
M, Tochigi A, Suemori S, Tohyama Y and Tohyama K: Effects of DNA
methyltransferase inhibitors (DNMTIs) on MDS-derived cell lines.
Exp Hematol. 41:189–197. 2013.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zeng W, Dai H, Yan M, Cai X, Luo H, Ke M
and Liu Z: Decitabine-Induced Changes in Human Myelodysplastic
Syndrome Cell Line SKM-1 Are Mediated by FOXO3A Activation. J
Immunol Res. 2017(4302320)2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Shin DY, Park YS, Yang K, Kim GY, Kim WJ,
Han MH, Kang HS and Choi YH: Decitabine, a DNA methyltransferase
inhibitor, induces apoptosis in human leukemia cells through
intracellular reactive oxygen species generation. Int J Oncol.
41:910–918. 2012.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Zhang W, Chen Y, Pei X, Zang Y and Han S:
Effects of Decitabine on the proliferation of K562 cells and the
expression of DR4 gene. Saudi J Biol Sci. 25:242–247.
2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Csizmar CM, Kim DH and Sachs Z: The role
of the proteasome in AML. Blood Cancer J. 6(e503)2016.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Vink J, Cloos J and Kaspers GJ: Proteasome
inhibition as novel treatment strategy in leukaemia. Br J Haematol.
134:253–262. 2006.PubMed/NCBI View Article : Google Scholar
|
|
42
|
McCloskey SM, McMullin MF, Walker B and
Irvine AE: The therapeutic potential of the proteasome in
leukaemia. Hematol Oncol. 26:73–81. 2008.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Cao Y, Qiu GQ, Wu HQ, Wang ZL, Lin Y, Wu
W, Xie XB and Gu WY: Decitabine enhances bortezomib treatment in
RPMI 8226 multiple myeloma cells. Mol Med Rep. 14:3469–3475.
2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Jin Y, Xu L, Wu X, Feng J, Shu M, Gu H,
Gao G, Zhang J, Dong B and Chen X: Synergistic efficacy of the
demethylation agent decitabine in combination with the protease
inhibitor bortezomib for treating multiple myeloma through the
Wnt/β-catenin pathway. Oncol Res. 27:729–737. 2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Grainger S, Traver D and Willert K: Wnt
signaling in hematological malignancies. Prog Mol Biol Transl Sci.
153:321–341. 2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Blum W, Schwind S, Tarighat SS, Geyer S,
Eisfeld AK, Whitman S, Walker A, Klisovic R, Byrd JC, Santhanam R,
et al: Clinical and pharmacodynamic activity of bortezomib and
decitabine in acute myeloid leukemia. Blood. 119:6025–6031.
2012.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Roboz GJ, Mandrekar SJ, Desai P, Laumann
K, Walker AR, Wang ES, Kolitz JE, Powell BL, Attar EC, Stock W, et
al: Randomized trial of 10 days of decitabine ± bortezomib in
untreated older patients with AML: CALGB 11002 (Alliance). Blood
Adv. 2:3608–3617. 2018.PubMed/NCBI View Article : Google Scholar
|
